The opportunity

An opportunity exists to subscribe to a private placement which will be used to fund LondonPharma's additional Phase lb/lla clinical trials in oncology in the UK for LON002 and the continued development of the company's product pipeline.

LondonPharma plans to raise £13 - 16 million over the next 18 to 24 months to progress LON002 to proof-of-efficacy in cancer patients, over a range of tumour types in both monotherapy and combination therapy settings.

During this period, the potential efficacy of artemisinins to treat Lyme disease and blood-fluke will be further determined through planned studies with a view to onward licensing to interested corporate parties.

Updated: 13/7/14

Print this page